FREMANEZUMAB-VFRM | B761089 | TEVA PHARMS USA
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Sep. 14, 2030 | Active | Computed |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 11541177(device) · relevance 85/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
9 AI-discovered patents, sorted by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Teva Pharmaceuticals International GmbH et al v. Eli Lilly and Company 4 patentsfremanezumab; galcanezumab | D. Mass. | 2021-06-07 | Terminated 2023-11-28 | — |
Teva Pharmaceuticals International GmbH et al v. Eli Lilly and Company 9 patentsfremanezumab (Teva product); galcanezumab (Eli Lilly product) | D. Mass. | 2018-09-27 | Terminated 2023-09-28 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.